In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

These include: Corticosteroid nasal spray. This initial treatment for nasal polyps aims to reduce the size or eliminate the growth of polyps in the child’s nose and reduce inflammation and ...

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Treatment can help most people relieve their symptoms. Healthcare providers may classify chronic rhinosinusitis based on whether or not you have nasal polyps (soft tissue growths in the lining of ...

An FDA nod 12 months ago allows it to be used by those who don’t have nasal polyps ... represents the only CRS treatment on the market for those with and without polyps. Optinose—which ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...